Written question asked by Anneliese Midgley (Labour) on Wednesday, 12 February 2025, in the House of Commons. It was due for an answer on Monday, 24 February 2025. It was answered by Karin Smyth (Labour) on Monday, 3 March 2025 on behalf of the Department of Health and Social Care.
Primodos: Research
- Question
-
To ask the Secretary of State for Health and Social Care, when the Medicines and Healthcare products Regulatory Agency will complete its consideration of the recommendations of the Commission on Human Medicines on the findings of the Danielsson et al on primodos.
- Answer
-
The Medicines and Healthcare products Regulatory Agency (MHRA), together with wider Government, has committed to reviewing any new scientific evidence which comes to light.
The new publication by Danielsson et al has been reviewed by the MHRA, and advice has been sought from the Government’s independent advisory body, the Commission on Human Medicines (CHM), who have provided their independent expert advice on our assessment of whether the findings of the latest publication justify a further review. The MHRA will consider the recommendations given by the CHM before deciding whether any further action is warranted.
The minutes of the November CHM meeting will be made publicly available through the GOV.UK website at the earliest opportunity.
Secondary information
- Type
- Written question
- Reference
- 31168
- Session
- 2024-26
- Related items
- Subjects
- Research Commission on Human Medicines Primodos
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2025-09-23 15:21:06 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-25/31168
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-25/31168
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-25/31168